Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €6.24 EUR
Change Today -0.061 / -0.97%
Volume 0.0
IX4 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GM
As of 2:20 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

iridex corp (IX4) Snapshot

Open
€6.19
Previous Close
€6.30
Day High
€6.24
Day Low
€6.19
52 Week High
03/23/15 - €9.88
52 Week Low
10/29/14 - €5.14
Market Cap
62.6M
Average Volume 10 Days
30.5
EPS TTM
--
Shares Outstanding
10.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IRIDEX CORP (IX4)

Related News

No related news articles were found.

iridex corp (IX4) Related Businessweek News

No Related Businessweek News Found

iridex corp (IX4) Details

IRIDEX Corporation develops, manufactures, markets, sells, and services medical laser systems and associated instrumentation for the treatment of the sight-threatening eye diseases. The company offers laser consoles, such as visible (yellow) photocoagulator consoles, visible (Green) photocoagulator consoles, infrared photocoagulator consoles, micropulse enabled consoles, and multi-wavelength laser system configurations; and ophthalmic delivery devices and other products, including TxCell scanning laser delivery systems, TruFocus laser indirect ophthalmoscopes, slit lamp adapters, and operating microscope adapters. Its ophthalmic delivery devices and other products also comprise EndoProbe, a fiber optic delivery device used for endophotocoagulation; G-Probe, a sterile single-use product used in procedures to treat medically and surgically uncontrolled glaucoma; DioPexy Probe, a hand-held instrument used in procedures to treat retinal tears; GreenTip Soft Tip Cannula used to visualize and access the proximity of the retina while performing a fluid air exchange during a vitrectomy procedure; and MoistAir in-line air humidifier that provides humidified air to the eye during fluid air exchange. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It sells and markets its products through a direct sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.

106 Employees
Last Reported Date: 04/2/15
Founded in 1989

iridex corp (IX4) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $387.4K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $323.5K
Vice President of Operations
Total Annual Compensation: $247.1K
Compensation as of Fiscal Year 2014.

iridex corp (IX4) Key Developments

IRIDEX Corporation Reports Preliminary Revenues Results for the Second Quarter and First Six Months of 2015

IRIDEX Corporation reported preliminary revenues of approximately $9.0 to $9.1 million and $19.8 to $19.9 million for the second quarter and first six months 2015, respectively.

IRIDEX Corporation Presents at 5th LD Micro Invitational Conference, Jun-03-2015 09:00 AM

IRIDEX Corporation Presents at 5th LD Micro Invitational Conference, Jun-03-2015 09:00 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States. Speakers: James H. Mackaness, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer.

Icare Finland plc and Iridex Corporation Enter into Distribution Cooperation

Icare Finland Plc signed a distribution agreement with Iridex Corporation related to Icare's TA01i instrument. Iridex plans to package the Icare TA01i with the Iridex Total Glaucoma Solution which includes the newly launched Cyclo G6 laser and the proprietary MicroPulse P3 device dedicated specifically to treat patients diagnosed with a range of glaucoma disease states. The Icare TA01i aids the physician in the diagnosis of glaucoma as well as post-operative assessment and monitoring of the patient's intra-ocular pressure. Iridex sold its first new Cyclo G6 glaucoma laser along with MicroPulse P3 disposable devices during the first quarter of 2015. The MicroPulse P3 device offers a repeatable, minimally invasive approach to slowing the progress of the disease and pushing off the need for more invasive surgical intervention. The Icare TA01i tonometer revolutionizes effective, early glaucoma detection by making the intra-ocular pressure measuring routine quick and easy for the patient as well as the physician.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IX4:GR €6.24 EUR -0.061

IX4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bovie Medical Corp $2.11 USD +0.01
Ellex Medical Lasers Ltd A$0.34 AUD +0.045
MGC Diagnostics Corp $5.25 USD -0.14
Misonix Inc $9.27 USD +0.11
Utah Medical Products Inc $54.67 USD -0.71
View Industry Companies
 

Industry Analysis

IX4

Industry Average

Valuation IX4 Industry Range
Price/Earnings 7.4x
Price/Sales 1.6x
Price/Book 2.1x
Price/Cash Flow 7.2x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRIDEX CORP, please visit www.iridex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.